Vir Biotechnology, Inc. - Common Stock (VIR)

The company is working to engage the immune system to attack cancer cells.

Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate cancer with manageable safety.

Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and PSMA in cancer therapies.

All 16 patients saw PSA declines of at least 50%. More than half reached a 90% decline in prostate-specific antigen levels.